Abstract
Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.
| Original language | English |
|---|---|
| Pages (from-to) | 1563-1569 |
| Number of pages | 7 |
| Journal | Metabolism: Clinical and Experimental |
| Volume | 57 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2008 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial. / Zimering, Mark B.; Anderson, Robert J.; Luo, Ping; Moritz, Thomas E.
In: Metabolism: Clinical and Experimental, Vol. 57, No. 11, 11.2008, p. 1563-1569.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial
AU - Zimering, Mark B.
AU - Anderson, Robert J.
AU - Luo, Ping
AU - Moritz, Thomas E.
PY - 2008/11
Y1 - 2008/11
N2 - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.
AB - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.
UR - http://www.scopus.com/inward/record.url?scp=53649096106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53649096106&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2008.06.012
DO - 10.1016/j.metabol.2008.06.012
M3 - Article
VL - 57
SP - 1563
EP - 1569
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 11
ER -